Study of BHV-1400 in IgA Nephropathy
Recruiting
Phase 1
Interventional Study
IgA Nephropathy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 20 (estimated)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
1\. Participants must have biopsy-confirmed IgA Nephropathy
Key Exclusion Criteria:
1. Any secondary IgAN
2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
Contacts